TORONTO: Graph Blockchain Inc. has secured an opportunity to procure, sell and distribute Personal Protective Equipment (PPE).

Graph has signed a nonbinding agreement on April 21, 2020 with Datametrex AI Limited that provides Graph a direct relationship with South Korean manufacturers of PPE and associated products.

With this opportunity and introduction Graph will work toward establishing supply and marketing agreements with the manufacturers over the coming weeks. Previous business activity in South Korea has enabled this opportunity and Graph looks forward to updating the market as and when material contracts become available.

Graph is presently in negotiation with PPE manufacturers and suppliers in alternate jurisdictions as well. There is no financial consideration contemplated between Graph and Datametrex at this time.

The list of products includes: EN14126 + Type 4 Level C/D Protective Clothing, hand sanitizers, and N95 /KF94 masks.

Certain products have already been submitted to Health Canada for fast-track approval. Graph Blockchain is moving quickly to confirm the amounts of products available and delivery timeframes for the supply of the PPE and associated products.

Presently Graph is in the process of finalising contract details and marketing materials.

President & COO, Christian Scovenna added: “We are excited to be in a position to help the world community in its time of need and we appreciate Datametrex AI Limited, reaching out to us with this opportunity. At Graph we see an opportunity that not only will allow the supply of PPE products to governments but also to private enterprises and Graph will also make these products available on its e-commerce marketplaces. Working with the suppliers and the manufacturing timelines will be key to complete a successful delivery chain.”

Health Canada and other governing health organisations must approve certain PPE products before they can be used in Canada or their respective jurisdictions. The EN14126 + Type 4 Level C/D Protective Clothing has already been submitted to Health Canada for approval.